Insider Trading Activity Atara Biotherapeutics, Inc. (NASDAQ:ATRA) – CEO Sold 2,800 shares of Stock

ME Staff
-
0

Insider Trading Activity For Atara Biotherapeutics, Inc. (NASDAQ:ATRA)

Isaac E Ciechanover , CEO of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) reportedly Sold 2,800 shares of the company’s stock at an average price of 16.94 for a total transaction amount of $47,432.00 SEC Form

Insider Trading History For Atara Biotherapeutics, Inc. (NASDAQ:ATRA)

  • On 10/21/2014 Domain Partners Viii, L.P., Major Shareholder, bought 248,159 with an average share price of $11.00 per share and the total transaction amounting to $2,729,749.00.View SEC Filing
  • On 2/18/2015 Carol Giltner Gallagher, Director, bought 11,000 with an average share price of $18.00 per share and the total transaction amounting to $198,000.00.View SEC Filing
  • On 3/10/2015 Joel S Marcus, Director, bought 4,000 with an average share price of $29.57 per share and the total transaction amounting to $118,280.00.View SEC Filing
  • On 4/23/2015 Isaac E Ciechanover, CEO, sold 5,200 with an average share price of $61.36 per share and the total transaction amounting to $319,072.00.View SEC Filing
  • On 5/22/2015 Isaac E Ciechanover, CEO, sold 4,000 with an average share price of $37.56 per share and the total transaction amounting to $150,240.00.View SEC Filing
  • On 5/29/2015 John Mcgrath, CFO, sold 10,000 with an average share price of $40.00 per share and the total transaction amounting to $400,000.00.View SEC Filing
  • On 6/1/2015 Christopher Haqq, Insider, sold 2,500 with an average share price of $41.47 per share and the total transaction amounting to $103,675.00.View SEC Filing

    • Analyst Ratings For Atara Biotherapeutics, Inc. (NASDAQ:ATRA)
    These are 2 Sell Ratings, 3 Buy Ratings .
    The current consensus rating for Atara Biotherapeutics, Inc. (NASDAQ:ATRA) is Hold (Score: 2.20) with a consensus target price of $25.75 , a potential (66.67% upside)

    Analyst Ratings History For Atara Biotherapeutics, Inc. (NASDAQ:ATRA)

    • On 3/9/2016 J P Morgan Chase & Co Lower Price Target of rating Market Outperform with a price target of $40.00 to $34.00
    • On 7/9/2016 JMP Securities Reiterated Rating Buy
    • On 9/15/2016 Goldman Sachs Group, Inc. (The) Downgraded rating Neutral to Sell with a price target of $23.00 to $16.00
    • On 3/16/2017 Citigroup Inc. Set Price Target of rating Sell with a price target of $10.00
    • On 4/21/2017 Canaccord Genuity Reiterated Rating Buy with a price target of $47.00
    • On 6/22/2017 Jefferies Group LLC Reiterated Rating Buy to Buy with a price target of $30.00
    • On 6/26/2017 William Blair Reiterated Rating Outperform

    Recent Trading Activity for Atara Biotherapeutics, Inc. (NASDAQ:ATRA)
    Shares of Atara Biotherapeutics, Inc. closed the previous trading session at 15.45 down -0.40 -2.52% with 201,696 shares trading hands.